The long-term goals of this research are an understanding of neurobehavioral mechanisms determining the addictive liabilities of drugs and the rational development of pharmacotherapies that will act on these mechanisms to reduce or eliminate addictive behavior. Recent research in this laboratory has focused on the neuropharmacology of iboga alkaloids (e.g., ibogaine) and congeners (e.g., 18-methoxycoronaridine) and their interactions with opioid and stimulant drugs of abuse. The methodology uses rats and involves measurement of intravenous drug self-administration and of drug effects on brain chemistry. In vivo microdialysis combined with HPLC (high performance liquid chromatography) is used to assay extracellular levels of biogenic amines (dopamine, serotonin) and their metabolites in discrete brain regions.
Specific aims i nclude the following: (1) The effects of ibogaine, its metabolite noribogaine and two iboga alkaloid congeners [18-methoxycoronaridine and 18-(N,N-dimethylaminoethyl)-coronaridine] on morphine and cocaine self-administration will continue to be investigated; it should be possible to develop agents that are at least as potent as ibogaine in suppressing drug self-administration but are much safer; iboga agents will be assessed on acquisition and on ongoing rates of drug self-administration behavior, in two models of relapse, and in a new oral model of nicotine preference. (2) Neurochemical mechanisms that might mediate putative anti-addictive effects of the same four iboga agents will be studied. In vivo microdialysis will be used to characterize the neurochemical actions of iboga agents and to define the receptor mechanisms mediating these effects; microdialysis will also be performed in rats self-administering morphine or cocaine in order to correlate neurochemical and behavioral effects of specific treatments. It is hypothesized that the unique pharmacology of these agents derives from a combination of actions at kappa opioid and NMDA receptors and at serotonin uptake sites. (3) Using GCMS (gas chromatography-mass spectrometry), the distribution and metabolism of the iboga agents will be studied. It is hypothesized that long-term effects of these agents are mediated by persistent low levels of the parent compounds and/or by active metabolites in discrete brain regions. This research may result in novel treatments for addictive disorders in humans.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA003817-13
Application #
2882557
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Acri, Jane
Project Start
1984-07-01
Project End
2002-02-28
Budget Start
1999-03-15
Budget End
2000-02-29
Support Year
13
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Albany Medical College
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Albany
State
NY
Country
United States
Zip Code
12208
Shoblock, James R; Maisonneuve, Isabelle M; Glick, Stanley D (2004) Differential interactions of desipramine with amphetamine and methamphetamine: evidence that amphetamine releases dopamine from noradrenergic neurons in the medial prefrontal cortex. Neurochem Res 29:1437-42
Pace, Christopher J; Glick, Stanley D; Maisonneuve, Isabelle M et al. (2004) Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. Eur J Pharmacol 492:159-67
Kuehne, Martin E; He, Liwen; Jokiel, Patrick A et al. (2003) Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem 46:2716-30
Maisonneuve, Isabelle M; Glick, Stanley D (2003) Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacol Biochem Behav 75:607-18
Steinmiller, Caren L; Maisonneuve, Isabelle M; Glick, Stanley D (2003) Effects of dextromethorphan on dopamine release in the nucleus accumbens: Interactions with morphine. Pharmacol Biochem Behav 74:803-10
Shoblock, James R; Sullivan, Eric B; Maisonneuve, Isabelle M et al. (2003) Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology (Berl) 165:359-69
Shoblock, James R; Maisonneuve, Isabelle M; Glick, Stanley D (2003) Differences between d-methamphetamine and d-amphetamine in rats: working memory, tolerance, and extinction. Psychopharmacology (Berl) 170:150-6
Zhang, Wenjiang; Ramamoorthy, Yamini; Tyndale, Rachel F et al. (2003) Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos 31:768-72
Glick, Stanley D; Maisonneuve, Isabelle M; Kitchen, Barbara A et al. (2002) Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol 438:99-105
Zhang, Wenjiang; Ramamoorthy, Yamini; Tyndale, Rachel F et al. (2002) Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. Drug Metab Dispos 30:663-9

Showing the most recent 10 out of 97 publications